...
首页> 外文期刊>Expert review of clinical immunology >Mediterranean fever gene variants and colchicine therapy in periodic fever, aphthous stomatitis pharyngitis, adenitis syndrome in a Mediterranean region
【24h】

Mediterranean fever gene variants and colchicine therapy in periodic fever, aphthous stomatitis pharyngitis, adenitis syndrome in a Mediterranean region

机译:地中海的地中海发热基因变体和血晶氨酸疗法,地中海地区的腺炎综合征,腺炎综合征

获取原文
获取原文并翻译 | 示例
           

摘要

Objectives: Periodic fever, aphthous stomatitis, pharyngitis, adenitis syndrome is characterized by recurrent episodes of fever. Attenuated disease severity was considered in patients with Mediterranean fever (MEFV) gene variations. Corticosteroids are highly effective in controlling the symptoms but usually cause more frequent episodes. Frequent fever episodes either initiated after the steroid therapy or as an initial disease characteristics are the most challenging feature. Methods: Sixty-seven patients were prospectively followed from September 2015 to January 2018. MEFV variants were searched in all patients. Colchicine therapy was initiated in patients with MEFV variants and with shortened intervals after the initiation of steroid therapy. Results: Heterozygous MEFV gene variants were detected in 23 patients (34.3%). Higher exon 10 allel frequencies were found in patients with frequent fever episodes. Among 26 patients with increased episodes, colchicine treatment decreased the number of the episodes in 8 of 10 (80%) and 4 of 16 (25%) patients with and without variants, respectively (p = 0.022). Fever duration decreased (3.26 +/- 1.38 vs. 1.57 +/- 0.57 days, p < 0.001) at the third month of therapy in variant(+) patients. Conclusion: In variant positive patients colchicine prophylaxis reduced the duration of attacks at the third months of therapy. Shortened intervals due to steroid therapy were increased at the sixth months of colchicine therapy.
机译:目的:定期发烧,口腔炎,咽炎,腺炎综合征的特征在于经常发烧发烧。在患有地中海发烧(MEFV)基因变化的患者中考虑了减毒的疾病严重程度。皮质类固醇在控制症状方面非常有效,但通常会导致更频繁的发作。频繁的发热剧集在类固醇疗法或初始疾病特征后启动是最具挑战性的特征。方法:前瞻性六十七名患者从2015年9月到2018年1月。所有患者都在搜查了MEFV变体。在患有MEFV变体的患者中启动了Colchicine疗法,并在服药治疗开始后缩短了间隔。结果:23例患者中检测到杂合MEFV基因变体(34.3%)。在频繁发热发作的患者中发现了更高的外显子10个等位基因。在26名患者中,血小藻嘌呤治疗分别减少了10(80%)和4名(25%)患者的8个(80%)和14例(25%)的患者的发作的数量(p = 0.022)。在变体(+)患者的第三个月治疗的第三个月,发烧持续时间减少(3.26 +/- 1.38 vs.1.57 +/- 0.57天,p <0.001)。结论:在变异阳性患者中,血氯氨酸预防患者在治疗的第三个月内发作持续时间。在第六个月的血氯化汀治疗中增加了由于类固醇治疗引起的间隔。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号